Discovery of Isobavachin, a Natural Flavonoid, as an Apolipoprotein E4 (ApoE4) Structure Corrector for Alzheimer's Disease

被引：0

作者：

Patil, Sachin P. ^{[1
,2
]}

Kuehn, Bella R. ^{[1
]}

Mccullough, Christina ^{[1
]}

Bates, Dean ^{[1
]}

Hazim, Hadil ^{[1
]}

Diallo, Mamadou ^{[1
]}

Francois, Naomie ^{[1
]}

机构：

[1] Widener Univ, NanoBio Lab, Chester, PA 19013 USA

[2] Widener Univ, Dept Chem Engn, Chester, PA 19013 USA

来源：

MOLECULES | 2025年 / 30卷 / 04期

关键词：

Alzheimer's disease; Apolipoprotein E4 (ApoE4); flavonoids; Isobavachin; structure correctors; protein stabilization; bioavailable compounds; molecular docking; molecular dynamics; AMYLOID-BETA-PROTEIN; UP-REGULATION; DOCKING; TAU; OPTIMIZATION; RISK;

D O I：

10.3390/molecules30040940

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by extensive neurodegeneration and consequent severe memory loss. Apolipoprotein E4 (ApoE4) is the strongest genetic risk factor for AD, with its pathological effects linked to structural instability and altered interactions with lipids and other important disease proteins including amyloid beta (A beta) and tau (tau). Therefore, correcting and stabilizing the ApoE4 structure has emerged as a promising therapeutic strategy for mitigating its detrimental effects. In this study, we investigated naturally occurring bioavailable flavonoids as ApoE4 stabilizers, focusing on their potential to modulate ApoE4 structure and function. A comprehensive investigation of a focused database using our integrated computational and experimental screening protocol led to the identification of Isobavachin as a potential corrector and stabilizer of ApoE4 structure. In addition, a few other bioavailable flavonoids with similar stabilizing properties were identified, albeit to a much lesser extent as compared to Isobavachin. The findings support the therapeutic potential of flavonoids as ApoE4 modulators and highlight Isobavachin as a lead candidate for further preclinical evaluation. These results provide new insights into the pharmacological targeting of ApoE4 and open avenues for the development of flavonoid-based, ApoE-directed therapies for AD.

引用

页数：19

共 49 条

[1] 2024 Alzheimer’s disease facts and figures, Alzheimers Dement, 20, pp. 3708-3821, (2024)
[2] Soria Lopez J.A., Gonzalez H.M., Leger G.C., Chapter 13-Alzheimer’s disease, Handb. Clin. Neurol, 167, pp. 231-255, (2019)
[3] Young-Pearse T.L., Lee H., Hsieh Y.C., Chou V., Selkoe D.J., Moving beyond amyloid and tau to capture the biological heterogeneity of Alzheimer’s disease, Trends Neurosci, 46, pp. 426-444, (2023)
[4] Patil S., Chan C., Palmitic and stearic fatty acids induce Alzheimer-like hyperphosphorylation of tau in primary rat cortical neurons, Neurosci. Lett, 384, pp. 288-293, (2005)
[5] Patil S., Sheng L., Masserang A., Chan C., Palmitic acid-treated astrocytes induce BACE1 upregulation and accumulation of C-terminal fragment of APP in primary cortical neurons, Neurosci. Lett, 406, pp. 55-59, (2006)
[6] Patil S., Melrose J., Chan C., Involvement of astroglial ceramide in palmitic acid-induced Alzheimer-like changes in primary neurons, Eur. J. Neurosci, 26, pp. 2131-2141, (2007)
[7] Haass C., Selkoe D.J., Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer’s amyloid beta-peptide, Nat. Rev. Mol. Cell Biol, 8, pp. 101-112, (2007)
[8] Walsh D.M., Selkoe D.J., Amyloid β-protein and beyond: The path forward in Alzheimer’s disease, Curr. Opin. Neurobiol, 61, pp. 116-124, (2020)
[9] Hong S., Beja-Glasser V.F., Nfonoyim B.M., Frouin A., Li S., Ramakrishnan S., Merry K.M., Shi Q., Rosenthal A., Barres B.A., Et al., Complement and microglia mediate early synapse loss in Alzheimer mouse models, Science, 352, pp. 712-716, (2016)
[10] Karran E., Mercken M., Strooper B., The amyloid cascade hypothesis for Alzheimer’s disease: An appraisal for the development of therapeutics, Nat. Rev. Drug Discov, 10, pp. 698-712, (2011)

← 1 2 3 4 5 →